Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide versus lenalidomide maintenance after ASCT in newly diagnosed multiple myeloma
CTR20232917Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Oct 2023
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iberdomide, lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Oct 2023; status: active.
02
Drugs
iberdomidelenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20232917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232917.